Cargando…

Advances in developing ACE2 derivatives against SARS-CoV-2

Extensive immune evasion of SARS-CoV-2 rendered therapeutic antibodies ineffective in the COVID-19 pandemic. Propagating SARS-CoV-2 variants are characterised by immune evasion capacity through key amino acid mutations, but can still bind human angiotensin-converting enzyme 2 (ACE2) through the spik...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Haoran, Lv, Panjing, Jiang, Jingrui, Liu, Yahui, Yan, Ruixi, Shu, Sainan, Hu, Bing, Xiao, Han, Cai, Kun, Yuan, Shuai, Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019897/ https://www.ncbi.nlm.nih.gov/pubmed/36934742 http://dx.doi.org/10.1016/S2666-5247(23)00011-3

Ejemplares similares

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
por: Zhang, Haoran, et al.
Publicado: (2022)

A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern
por: Lv, Panjing, et al.
Publicado: (2022)

Structural Insights into Mouse H-FABP
por: Wang, Lili, et al.
Publicado: (2022)

Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021)

ACE2-independent infection of T lymphocytes by SARS-CoV-2
por: Shen, Xu-Rui, et al.
Publicado: (2022)

Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro
por: Lu, Jiayu, et al.
Publicado: (2021)

Evolution of ACE2-independent SARS-CoV-2 infection and mouse adaption after passage in cells expressing human and mouse ACE2
por: Yan, Kexin, et al.
Publicado: (2022)

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
por: Iwanaga, Naoki, et al.
Publicado: (2021)

Advanced Analysis of Biosensor Data for SARS-CoV-2 RBD and ACE2 Interactions
por: Forssén, Patrik, et al.
Publicado: (2020)

Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity
por: Batlle, Daniel, et al.
Publicado: (2022)

Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness
por: Faisal, H.M. Nasrullah, et al.
Publicado: (2021)

A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants
por: Duan, Xiaomin, et al.
Publicado: (2022)

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
por: Du, Yanyun, et al.
Publicado: (2021)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
por: He, Ming-Feng, et al.
Publicado: (2022)

Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2
por: Mou, Huihui, et al.
Publicado: (2020)

Soluble ACE2 in SARS-CoV-2 infection
por: Allison, Susan
Publicado: (2021)

ACE2: the molecular doorway to SARS-CoV-2
por: Medina-Enríquez, Miriam Marlene, et al.
Publicado: (2020)

Fish ACE2 is not susceptible to SARS-CoV-2
por: Xie, Shi-Zhe, et al.
Publicado: (2022)

Response to Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity
por: Yeung, Man Lung, et al.
Publicado: (2022)

An ace model for SARS-CoV-2 infection
por: Major, Jack, et al.
Publicado: (2020)

Cross-species recognition of SARS-CoV-2 to bat ACE2
por: Liu, Kefang, et al.
Publicado: (2021)

The molecular basis for SARS-CoV-2 binding to dog ACE2
por: Zhang, Zengyuan, et al.
Publicado: (2021)

Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2
por: Shu, Chuan-Jun, et al.
Publicado: (2021)

Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster
por: Zhang, Ya-Nan, et al.
Publicado: (2023)

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
por: Yan, Renhong, et al.
Publicado: (2020)

Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
por: Shen, Yaping, et al.
Publicado: (2022)

ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
por: Rawle, Daniel J., et al.
Publicado: (2021)

Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
por: Mou, Huihui, et al.
Publicado: (2021)

The impact of ACE2 and co‐factors on SARS‐CoV‐2 infection in colorectal cancer
por: Li, Shuwei, et al.
Publicado: (2022)

Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
por: Lan, Jun, et al.
Publicado: (2022)

An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice
por: van Oosten, Linda, et al.
Publicado: (2022)

ACE2 expression is regulated by AhR in SARS-CoV-2-infected macaques
por: Lv, Jiadi, et al.
Publicado: (2021)

The flexibility of ACE2 in the context of SARS-CoV-2 infection
por: Barros, E. P., et al.
Publicado: (2020)

Therapeutic Strategies for SARS-CoV-2 acting on ACE-2
por: Vitiello, A., et al.
Publicado: (2021)

Endocrine Significance of SARS-CoV-2’s Reliance on ACE2
por: Lazartigues, Eric, et al.
Publicado: (2020)

The flexibility of ACE2 in the context of SARS-CoV-2 infection
por: Barros, Emilia P., et al.
Publicado: (2021)

Oral cancer and ACE2 receptor of SARS-CoV-2
por: Martelli-Júnior, Hercílio, et al.
Publicado: (2020)

Endocrine significance of SARS-CoV-2’s Reliance on ACE2
por: Chappell, Mark C
Publicado: (2020)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

The glycosylation in SARS-CoV-2 and its receptor ACE2
por: Gong, Yanqiu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bvn8kk93sdbi274grb8bng131f